» Articles » PMID: 34570334

The Attitudes of Brazilian Breast Surgeons on Axillary Management in Early Breast Cancer-10 Years After the ACOSOG Z0011 Trial First Publication

Abstract

Purpose: To evaluate the impact of the ACOSOG Z0011 trial on axillary breast cancer surgery management in Brazil following publication of that study (2010) and again in 2020.

Patients And Methods: A survey of members of the Brazilian Society of Mastology.

Results: Of 1627 breast surgeons, 799 (49.1%) completed and returned the questionnaire. For patients with the Z11 inclusion criteria, following detection of a positive sentinel lymph node (SLN), axillary dissection (AD) was recommended by 99.2% of respondents before publication of the study, 47.5% in 2010 and 18.5% in 2020 (p < 0.001). In breast-conserving surgery, if there were micro-metastases, 2.6% would perform AD, 30.3% axillary radiotherapy, and 67.1% no additional axillary treatment, while with macro-metastases, these proportions were 21.3%, 52.2%, and 26.5%, respectively. In cases of mastectomy and of nodal extracapsular extension, 43.4% and 36% of surgeons, respectively, recommended AD. For clinically negative axilla and suspicious findings at ultrasonography, 69% of the surgeons would apply the Z11 approach. Most applied the Z11 criteria in cases of younger patients (83.6%) and triple-negative and/or HER2 positive tumors (74%). AD was significantly more likely to be recommended by surgeons who did not work in academic institutes, who worked in locations other than capital cities, who were not board-certified, and who were ≥ 50 years old.

Conclusions: This survey revealed substantial changes in axillary surgery management in cN0/pathologically positive SLN, particularly following publication of the updated Z11 results and other similar studies. A better education environment and long-term follow-up were factors associated with the incorporation of Z11-related changes in practice.

Citing Articles

Research gaps in sentinel lymph node biopsy in breast cancer.

Hamdy O Oncologist. 2024; 29(9):e1101-e1103.

PMID: 38837063 PMC: 11379629. DOI: 10.1093/oncolo/oyae133.


Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology.

Freitas-Junior R, de Oliveira V, Frasson A, Cavalcante F, Mansani F, Mattar A BMC Cancer. 2022; 22(1):1201.

PMID: 36419031 PMC: 9682792. DOI: 10.1186/s12885-022-10250-x.


Identification of the lymph node metastasis-related automated breast volume scanning features for predicting axillary lymph node tumor burden of invasive breast cancer a clinical prediction model.

Zhao F, Cai C, Liu M, Xiao J Front Endocrinol (Lausanne). 2022; 13:881761.

PMID: 35992122 PMC: 9388849. DOI: 10.3389/fendo.2022.881761.

References
1.
Magnoni F, Galimberti V, Corso G, Intra M, Sacchini V, Veronesi P . Axillary surgery in breast cancer: An updated historical perspective. Semin Oncol. 2020; 47(6):341-352. DOI: 10.1053/j.seminoncol.2020.09.001. View

2.
Giuliano A, Haigh P, Brennan M, Hansen N, Kelley M, Ye W . Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000; 18(13):2553-9. DOI: 10.1200/JCO.2000.18.13.2553. View

3.
Giuliano A, Dale P, Turner R, Morton D, Evans S, Krasne D . Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995; 222(3):394-9; discussion 399-401. PMC: 1234825. DOI: 10.1097/00000658-199509000-00016. View

4.
Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V . A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349(6):546-53. DOI: 10.1056/NEJMoa012782. View

5.
Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V . Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010; 251(4):595-600. DOI: 10.1097/SLA.0b013e3181c0e92a. View